Prof. Dr. med. Peter Fasching

Professur für Translationale Frauenheilkunde und Geburtshilfe

Multicenter evaluation of blood-based biomarkers for the detection of endometriosis and adenomyosis: A prospective non-interventional study (2023) Burghaus S, Drazic P, Wölfler M, Mechsner S, Zeppernick M, Meinhold-Heerlein I, Mueller MD, et al. Journal article Evaluation of European-based polygenic risk score for breast cancer in Ashkenazi Jewish women in Israel (2023) Levi H, Carmi S, Rosset S, Yerushalmi R, Zick A, Yablonski-Peretz T, Wang Q, et al. Journal article Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer (2023) Slamon DJ, Fasching P, Hurvitz S, Chia S, Crown J, Martín M, Barrios CH, et al. Journal article Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study (2023) Curigliano G, Dunton K, Rosenlund M, Janek M, Cathcart J, Liu Y, Fasching P, Iwata H Journal article Association Between Obesity and Circulating Tumor Cells in Early Breast Cancer Patients (2023) Tzschaschel M, Friedl TW, Schochter F, Schütze S, Polasik A, Fehm T, Pantel K, et al. Journal article Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States (2023) Huang M, Fasching P, Haiderali A, Xue W, Yang C, Pan W, Zhou ZY, et al. Journal article Lifestyle and personal factors associated with having macroscopic residual disease after ovarian cancer primary cytoreductive surgery (2023) Phung MT, Webb PM, DeFazio A, Fereday S, Lee AW, Bowtell DD, Fasching P, et al. Journal article Update Breast Cancer 2023 Part 2 - Advanced-Stage Breast Cancer. (2023) Lux MP, Hartkopf AD, Fehm TN, Welslau M, Müller V, Schütz F, Fasching P, et al. Journal article Correction: PredictCBC-2.0: a contralateral breast cancer risk prediction model developed and validated in ~ 200,000 patients (Breast Cancer Research, (2022), 24, 1, (69), 10.1186/s13058-022-01567-3) (2022) Giardiello D, Hooning MJ, Hauptmann M, Keeman R, Heemskerk-Gerritsen BA, Becher H, Blomqvist C, et al. Journal article, Erratum Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1 (2022) Huang M, O'Shaughnessy J, Haiderali A, Pan W, Hu P, Chaudhuri M, Le Bailly De Tilleghem C, et al. Journal article